AIMD.P AIM4 Ventures

Annovis Bio to Present at the 2020 BIO Investor Forum

Annovis Bio to Present at the 2020 BIO Investor Forum
EN
12/10/2020

Underlying

AIMD.PAIM4 Ventures

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on AIM4 Ventures

 PRESS RELEASE
Free
AIMD.P AIM4 VENTURES

Annovis Secures DSMB Approval to Advance Pivotal Phase 3 Trial of Bunt...

Annovis Secures DSMB Approval to Advance Pivotal Phase 3 Trial of Buntanetap in Alzheimer’s Disease MALVERN, Pa., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced that an independent Data and Safety Monitoring Board (DSMB) has issued a positive recommendation regarding the safety of buntanetap at 6 months, supporting the continuation...

February 12, 2026 1 EN
 PRESS RELEASE
Free
AIMD.P AIM4 VENTURES

Annovis Announces Open-Label Extension Study for Parkinson's Disease P...

Annovis Announces Open-Label Extension Study for Parkinson's Disease Patients Enrollment will begin in January 2026 Participants will be treated with buntanetap for 36 months The study aims to enroll 500 patients MALVERN, Pa., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced it will begin an Open-Label Extension (OLE) study in January 2026 to evaluate th...

December 18, 2025 1 EN
 PRESS RELEASE
Free
AIMD.P AIM4 VENTURES

Annovis to Host Corporate Update Webinar on January 28, 2026

Annovis to Host Corporate Update Webinar on January 28, 2026 MALVERN, Pa., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced it will host a corporate update webinar followed by a live Q&A session. The webinar will feature Maria Maccecchini, Ph.D., President and CEO, who will provide an overview of the Company’s recent progress, ongoing clinical programs, an...

December 16, 2025 1 EN
 PRESS RELEASE
Free
AIMD.P AIM4 VENTURES

Annovis To Present at the 2025 Annual Meeting of the Parkinson Study G...

Annovis To Present at the 2025 Annual Meeting of the Parkinson Study Group MALVERN, Pa., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced it will present at the 2025 Annual Meeting of the Parkinson Study Group (PSG), taking place December 4-6, 2025 in San Diego, California. The presentation builds on momentum from the Company’s recent , showing that patien...

December 3, 2025 1 EN
 PRESS RELEASE
Free
AIMD.P AIM4 VENTURES

Annovis Announces Two Presentations at the CTAD 2025 Conference

Annovis Announces Two Presentations at the CTAD 2025 Conference MALVERN, Pa., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced two presentations at the 18th Clinical Trials on Alzheimer's Disease (CTAD) conference, taking place December 1-4, 2025 in San Diego, California. The presentations will highlight progress across the Alzheimer’s and Parkinson’s prog...

November 24, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch